Summary
Management framed growth as increasingly supported by later-stage molecule progression, rising capacity utilization and operating efficiency.
Guidance
- FY26 revenue guidance RMB51.3–53.0B
- 35%FY26 continuing-operations revenue growth 35%–39%
- 45%FY26 discovery business revenue growth approximately 45%
Notable disclosures
- 465 quality audits and inspections in H1; none had serious findings.
- 21 customer information-security audits took place in H1.
- 15 more commercialized and Phase III programs were added in H1.
- Changzhou site construction started ahead of schedule to meet customer demand.
Risks raised
- Market fluctuations and exchange-rate volatility were identified as challenges to the full-year outlook.
Tone: Confident 0.82
Management highlighted stronger continuing-operations growth expectations, expanding later-stage pipelines and improved margins, while acknowledging market and currency volatility.
Who spoke
Company
- Unidentified Management
- Chen MinzhangCo-Chief Executive Officer
- Yang QingCo-Chief Executive Officer
Full transcript
Analyst questions are marked with a bar. Timestamps are into the recording.
Prepared remarks
Unidentified Management
Hello, dear investors. Welcome to WuXi AppTec's 2026 interim results presentation. We are very grateful to the Shanghai Stock Exchange. For the Shanghai ... Center's ... to provide the company with this platform for communication and exchange with investors. To increase the company's opportunities to present itself to the capital market. To deepen investors' understanding of the company. To convey the company's investment value in a timely manner. Here, on behalf of the company, I would like to express our sincere respect to all the friends participating in today's online exchange. Now, please allow me to introduce the company's management attending this results presentation. They are Dr. Chen Minzhang, the company's Co-Chief Executive Officer. Dr. Yang Qing, the company's Co-Chief Executive Officer.
Mr. Shi Minyu, the company's Chief Financial Officer. Dr. Wu Hao, the company's Global Head of Legal. And Dr. Yu Wei, the company's independent director. On the evening of August 3. The company announced its 2026 interim results. And published the presentation materials for the results on the company website. Before the results discussion. We would like to note that today's discussion contains forward-looking statements. Therefore, you should be aware that any reliance on forward-looking statements involves known and unknown risks and uncertainties. In addition, to supplement the financial statements prepared by the company in accordance with International Financial Reporting Standards. We provide adjusted Neng RFS financial data.
We believe adjusted financial metrics help in understanding and evaluating business performance and operating trends. And eliminate unusual or non-recurring items that are not representative of the company's business performance. However, you should not consider the above adjusted data in isolation. Or regard it as a substitute for results prepared in accordance with International Financial Reporting Standards. Please note. All intellectual property rights and powers in the information and materials relating to this meeting belong to WuXi AppTec. No one may, without the company's prior permission. Make audio or video recordings of the meeting. Or disseminate meeting-related materials externally in any form. This meeting is not intended to provide a complete account of the relevant matters. For relevant information, please refer to the documents and information disclosed by the company on the Shanghai Stock Exchange.
The Hong Kong Stock Exchange, and the company's website. Next, we invite management to introduce the company's business performance. In the first half of the second record machine of 2026. The company's revenue and profit both achieved strong growth. First-half operating revenue reached 28.9 billion yuan. Revenue from continuing operations grew 48% year over year. The company's adjusted IFRS net profit attributable to owners. Grew 83.2% year over year. Reaching 11.57 billion yuan. At the same time, the adjusted IFRS net profit margin. Increased further by 9.7 percentage points. To 40%. The company continues to focus on its core CRDMO strategy. Further improving business predictability. As of the end of June 2026. The company's continuing-operations backlog reached 66.43 billion yuan.
An increase of 25.2% year over year. As you can see on this slide. The company, as an innovation enabler in the industry. Actively promotes sustainable development. And puts global initiatives into practice. Continuing to receive recognition and assurance from authoritative organizations. In 2026, the company retained its MLCI ESG. Highest manufacturing A rating. And has maintained a leadership rating for 6 consecutive years. In addition, the company's outstanding performance was recognized by. CBT EcoVirus. It received high recognition from authoritative international organizations such as S&P Global. The company established a greenhouse gas emissions target that has received SBTi recognition. It is also a member of the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative as a supplier partner.
We will continue to advance our sustainable development strategy. We are firmly committed to our promises to all sectors of society. In the more than 20 years since our establishment, we have always upheld the principle of putting customers first, followed the industry's highest quality systems and compliance standards, and fulfilled our commitment to protecting our customers' intellectual property. In the first half of 2020, the company underwent quality audits and inspections from global customers and regulatory agencies, as well as independent third parties, for a total of 465 times. Global customers conducted information security audits a total of 21 times. This means the company hosted more than three quality audits per day on average and more than three information security audits per month.
None had any serious findings. The company's 20 major operating sites have received the international ISO/IEC 27001 Information Security Management System certification, covering all major operating sites in China. Intellectual property is the lifeline shared by the company and its customers. We adhere to integrity as the foundation of our business. We have zero tolerance for unethical conduct. These are the core values of WuXi AppTec. They are our highest responsibility and commitment.
Next, I will introduce the business performance of each of our segments. The WuXi Chemistry pipeline continues to expand and is steadily advancing to later stages. We are accelerating forward-looking capacity planning. As our pipeline molecules advance to later stages, the newly added capacity from recent years is being released at an increasing pace. In the first half of 2026, WuXi Chemistry revenue grew 53.3% year over year reached 24.99 billion yuan At the same time, benefiting from the continuous optimization of production processes and growth in late-stage clinical and commercial projects, which continued to improve capacity utilization, in the first half, adjusted IFRS gross margin continued to rise to 56.4%. This was an increase of 7.4 percentage points year over year.
The company is accelerating forward-looking capacity planning. We have started construction of the new Changzhou site ahead of schedule to better meet growing customer demand. In small-molecule drug discovery, the R2 business continues to feed downstream business. Over the past 12 months, we successfully synthesized and delivered more than 440,000 novel compounds. In the first half of this year, 155 molecules progressed from R2 to the D stage. As the integrated capabilities of the CRDMO platform continue to strengthen, the company continues to increase the internal progression of molecules through different stages. Small-molecule supply, research and manufacturing, the D&M business maintained strong growth. The small-molecule CDMO pipeline continues to expand. This is thanks to the business model's continued ability to attract high-quality molecules.
The pipeline is steadily progressing to later stages, along with forward-looking capacity planning and the team's efficient execution. In the first half of 2026, small-molecule D&M business revenue reached RMB 14.99 billion, up 72.7% year over year. The new molecule discovery business maintained rapid growth. Revenue from the discovery business was 7.26 billion yuan in the first half. It increased 44.3% year on year. Full-year revenue from the discovery business is expected to grow by approximately 45%. In the first half, the number of customers served by the discovery DNM business increased 39% year on year. The number of molecules served increased 68% year on year. Driven by both following molecules and winning molecules, WuXi AppTec's small-molecule CRDMO pipeline is converting efficiently, continuously attracting high-quality molecules and driving sustained business development.
This also demonstrates customers' strong recognition of our technical capabilities, service efficiency, and quality system. In small-molecule R&D over the past 12 months, we delivered more than 440,000 new compounds. While maintaining strong delivery scale, the synthetic complexity of these compounds has also continued to increase, demonstrating the strong demand among early-stage R&D customers for high-quality services. On this basis, we continuously enhance internal synergies, strengthen molecule conversion from the R stage to the D stage, and continuously generate leads for the downstream DNM business. At the DNM stage, in the first half of 2026, we added 699 molecules, including 155 molecules advanced from the R2 stage. As of the end of June, the small-molecule DNM pipeline had reached a total of 3,731 molecules, including 95 commercialized molecules, 94 Phase III clinical programs, 394 Phase II clinical programs, and 3,148 preclinical and Phase I clinical programs.
There were 15 more commercialized and Phase III programs in the first half. For the growth in pipelines at these later stages, we know that the molecules are continuously increasing in complexity and quality, and that collaboration with customers is deepening. All of this will drive the company's continued business development in the future.
Chen MinzhangCo-Chief Executive Officer
Next, I will hand over to Dr. Yang Xin, PoCEO, to introduce the progress of WuXi AppTec and WuXi Biology. President Yang.
Yang QingCo-Chief Executive Officer
Thank you, Mr. Chen. Please turn to page 12. In the first half of 2026, WuXi Testing generated revenue of 2.48 billion yuan, up 31.5% year on year. Among this, revenue from drug safety evaluation grew 42.8% year on year, maintaining its leading position in the Asia-Pacific region. We benefited from differentiated capability building and economical operations management. WuXi Testing's gross margin continued to improve quarter on quarter. In the first half, the adjusted non-IFRS gross margin increased 11.3% year on year to 38.6%. The company empowers customers' global collaboration and accelerates new drug innovation. The new molecule types business continued to gain momentum. Revenue contribution in the first half increased to more than 35%. We maintained a leading position in multiple areas.
Meanwhile, the drug metabolism and pharmacokinetics business continued to advance its research and service capabilities, achieving a 7×24-hour automated and intelligent closed-loop bioanalysis operational process. This further consolidated our leading position in the industry. In addition, the Suzhou facility successfully completed its first project inspection by Korea's MFDS in the first half, and again successfully completed a project inspection by Japan's PMDA. This also marked the Suzhou facility's achievement since 2024 of passing PMGA inspections successfully for the third consecutive time. WuXi Biology adheres to a science-driven philosophy, and takes a forward-looking approach to drug discovery hotspots and differentiated capabilities, while actively expanding its global business. Efficiently channeling leads to the company's CRDMO business model Continuously bringing the company more than 20% of its new customers WUXI Biology connects its in vitro and in vivo drug discovery businesses Through cross-regional collaboration and integrated services in high-interest areas Efficiently empowering global customers Revenue in the first half of 2026 was 1.39 billion yuan An increase of 11.2% year on year WUXI Biology continued to deepen business integration and improve operational efficiency The adjusted non-IFRS gross margin in the first half increased 0.6% year on year to 37% The business kept pace with market conditions and maintained a flexible pricing strategy Continuing to realize the value of lead generation Technology on the in vitro integrated screening platform accelerated its breakthroughs At the same time, we iterated our automation capabilities to improve operational efficiency Continuing to win new customers Our in vivo pharmacology capabilities continued to improve Driving rapid revenue growth In the first half, revenue from new molecule types accounted for more than 35% Rapid growth in new customers from multiple new molecule areas Next, I will hand the time over to Mr. Shi to introduce the company's financial performance in the first half of 2026 Mr. Shi, please Thank you, Mr. Yang Let's review the company's overall financial data together In the first half of 2026, the company achieved strong growth in both revenue and profit This result was due to greater success with products from multiple customers It was also due to the CRDMO business model The front end continuously brought in new customers and new molecules Bringing continuity to our business It also enabled us to plan key capacity and capabilities in advance At the same time, as efficient new capacity was released quarter by quarter It met the growing demand for the later stages of drug development and commercialization That continued to grow On this basis The company continued to promote high-quality development Continuously strengthening the development of new technologies and capabilities Further improving overall production and operational efficiency In the first half of 2026 The company's adjusted non-IFRS gross profit reached 15.58 billion yuan The corresponding adjusted non-IFRS gross margin Increased 9.4 percentage points year on year To 53.9% Adjusted non-IFRS net profit in the first half reached 11.57 billion yuan An increase of 83.2% year on year The corresponding adjusted net profit margin for the first half Increased 9.7 percentage points year on year to 40%.
In the first half, net profit attributable to shareholders of the parent company, excluding non-recurring items, reached 10.57 billion yuan, an increase of 89.4% year on year Net profit attributable to shareholders of the parent company in the first half reached 11.08 billion yuan An increase of 29.4% year on year The difference in growth rates was mainly because net profit attributable to shareholders of the parent company in the first half of last year Included investment income of 3.2 billion yuan from the sale of part of the equity in an associated company Faced with a complex market environment The company has always remained firmly focused on its unique CRDMO business model Continuously improving our operations and management capabilities Serving customers with the utmost commitment And achieving ideal financial performance Thanks to sustained business development Efficient operations And continuously improving financial management capabilities In the first half of 2026 The company's adjusted operating cash flow reached 9.98 billion yuan An increase of 41.3% year on year Fully demonstrating the company's sustainable, high-quality development At the same time, the company is actively accelerating the development of global capacity.
In the first half, the company's capital expenditure totaled 2.96 billion yuan. Next, I will hand the floor back to Mr. Chen to share the company's future outlook. The company continues to focus on the core strengths of its unique integrated CRDMO model and accelerate the development of its global capacity footprint and capabilities. to capture the certainty of customers' demand for empowerment, provide customers with highly efficient and exceptional service, and help patients around the world and drive the company's long-term development. At the same time, the company will deepen its refined management and operations and continue to improve production efficiency and enhance corporate resilience to cope with a complex and changing business environment. We are pleased by the greater success of multiple customer products, as well as the company's unique CRDMO model and excellent management execution.
The company has comprehensively raised its full-year performance guidance to an expected overall company revenue this year of 51.3 to 53.0 billion yuan, up from 58.5 to 60.5 billion yuan. The year-on-year growth rate of continuing-operations revenue, previously 18% to 22%, has been raised to 35% to 39%. The company will continue to drive high-quality growth and steadily release the benefits of scale, make efforts in refined operational management, and efficiently manage new capacity in advance. Challenges such as market fluctuations and exchange rate volatility give us confidence that this year we will maintain stable and resilient adjusted non-IFRS attributable net profit growth. At the same time, to better meet growing customer demand, we are therefore further accelerating our global capacity footprint and starting construction of the Changzhou new site ahead of schedule.
The company's capital expenditure for 2026 is expected to be raised from 6.5 to 7.0 billion yuan to 7.5 to 8.5 billion yuan. With business growth and efficiency improvements, this year, adjusted free cash flow is expected to increase from 10.5 to 11.5 billion yuan to 13.5 to 14.5 billion yuan. While accelerating the development of global capacity and capabilities, the company continues to reward shareholders and share the value of the company. In the first half, the company completed payment of the 2025 annual cash dividend totaling 4.71 billion yuan. At the same time, building on the first implementation of an interim dividend of 300 million yuan in 2025, the company's board of directors has approved a further increase in the scale of the 2026 interim dividend to a cash dividend of 5.1 yuan per share totaling approximately 1.5 billion yuan.
In the current complex and changing environment, the company's long-term stable development requires an exceptionally capable and steadfast management team. In the first half, the company completed the purchase of 2.5 billion Hong Kong dollars of H shares and 1 billion yuan of A shares to continuously incentivize and retain talent, bring management together, and strengthen the company's operational management resilience. At the same time, these will not dilute the interests of existing shareholders. The annual general meeting of shareholders has now approved the 2026 H-share restricted share award plan. The company's board of directors will further launch the 2026 A-share employee affairs plan. It will then be submitted for approval at an extraordinary shareholders' meeting.
Thank you all for listening.
Questions and answers
Unidentified Management
Thank you to the company's management for the presentation. I believe everyone now has a better understanding of the company's operating performance. We will now move on to the written interactive Q&A session of this results presentation.
Other Wuxi Apptec earnings calls
- written Q&A, August 27, 2026
Management framed the raised outlook as demand-led pipeline conversion, while emphasizing execution, capacity readiness and resilience amid geopolitical and currency headwinds.
Aug 28, 2026Positive0.48 - written Q&A, April 12, 2026
Management framed growth around CRDMO capacity expansion and operational efficiency, while offering little quantified detail on pricing, capital allocation or customer concentration.
Apr 13, 2026Mildly positive0.35 - written Q&A, November 11, 2025
Management framed durable CRDMO demand and capacity expansion as the growth engine, while emphasizing policy uncertainty and declining to quantify near-term peptide ramp or pricing effects.
Nov 12, 2025Mildly positive0.35 - written Q&A, August 28, 2025
Management framed the call around strong demand and execution, raising its full-year outlook while balancing shareholder returns with global capacity investment.
Aug 29, 2025Confident0.75
About this transcript
The call was held in another language and translated. The summary, guidance, analyst focus, and tone are automated and should be checked against the call before being relied on. Names and figures can be misheard. Listen to the replay.